drugset / Trial / NCT00612417

Effect of Recombinant FVIII in Healthy Male Subjects Treated With TB-402

NCT00612417

Phase 1 Completed 12 enrolled ThromboGenics BioInvent International AB · collab
RandomizedParallel-groupDouble-blind

Summary

Single administration of recombinant FVIII/placebo in healthy male subjects who have been treated with a single dose of anti-factor VIII antibody, TB-402

Timeline

Start
2008-01
Primary completion
2008-03
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject turoctocog alfa Protein / enzyme biologic
Background TB-402 Monoclonal antibody

Indications

No indication recorded.